| Friend, Richard |
NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease |
|
|
| Active, not recruiting | 1/2 | 75 | RoW | LASN01, Placebo | Lassen Therapeutics 1 PTY LTD | Pulmonary Fibrosis, Thyroid Eye Disease | 02/25 | 02/25 | | |
PNH, NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria () Patients |
|
|
| Recruiting | 1/2 | 50 | Europe, RoW | ADX-038, siRNA, Placebo, Saline | ADARx Pharmaceuticals, Inc., ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 03/26 | 09/26 | | |
ACTRN12621000103864: To assess the safety, tolerability and pharmacokinetics of INCB86550 in healthy adult population. |
|
|
| Not yet recruiting | 1 | 75 | | | Incyte Corporation, Incyte Corporation | Cancer | | | | |
ACTRN12621001077853p: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women |
|
|
| Not yet recruiting | 1 | 80 | | | Keros Therapeutics, Keros Therapeutics | Healthy Postmenopausal Women | | | | |
ACTRN12620000013965: A Study to Compare the Pharmacokinetic Similarity of JHL1266 versus Prolia in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 225 | | | JHL Biotech Australia Pty Ltd., JHL Biotech Australia Pty Ltd. | Osteoporosis | | | | |
ACTRN12622000293763: A study comparing extended release and immediate release formulations of EQ121 in adult healthy volunteers of Chinese descent- Part C |
|
|
| Withdrawn | 1 | 10 | | | EQRx International, Inc., EQRx International, Inc. | Rheumatoid Arthritis | | | | |
ACTRN12621001216808: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of EQ121 following oral single (Part 1) and multiple (Part 2) ascending dose administration in healthy subjects. |
|
|
| Active, not recruiting | 1 | 104 | | | EQRx, Inc, EQRx, Inc | Rheumatoid Arthritis | | | | |
ACTRN12621001077853: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women |
|
|
| Completed | 1 | 80 | | | Keros Therapeutics, Inc., Keros Therapeutics, Inc. | Healthy Postmenopausal Women | | | | |
ACTRN12621000514808: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of
mEphA4-Fc |
|
|
| Completed | 1 | 28 | | | NuNerve Pty. Ltd., NuNerve Pty. Ltd. | Amyotrophic Lateral Sclerosis | | | | |
ACTRN12622000292774: A study comparing extended release and immediate release formulations of EQ121 in healthy adult volunteers- Part B |
|
|
| Completed | 1 | 12 | | | EQRx International, Inc., EQRx International, Inc. | Rheumatoid Arthritis | | | | |
ACTRN12622000307707: A study comparing extended release and immediate release formulations of EQ121 following single doses in healthy adult volunteers- Part A |
|
|
| Completed | 1 | 40 | | | EQRx International, Inc., EQRx International, Inc. | Rheumatoid Arthritis | | | | |
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults |
|
|
| Recruiting | 1 | 90 | RoW | T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004 | Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd. | Obesity, Type 2 Diabetes Mellitus | 07/24 | 08/24 | | |
NCT05174013: Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants |
|
|
| Completed | 1 | 32 | RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 06/23 | 06/23 | | |
| Completed | 1 | 88 | | | IPC Research, LLC, IPC Research, LLC | complement mediated diseases | | | | |
NCT05225857: A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women |
|
|
| Completed | 1 | 90 | RoW | AGA2118, Placebo | Angitia Biopharmaceuticals, Angitia Australia Pty Ltd | Osteoporosis | 01/24 | 01/24 | | |
NCT05215912: A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers |
|
|
| Completed | 1 | 31 | RoW | TNB-738 | TeneoFour Inc., Novotech (Australia) Pty Limited | Healthy Volunteer | 05/23 | 07/23 | | |
| Recruiting | 1 | 100 | US, RoW | AT-02, AT-02 (Placebo) | Attralus, Inc., Novotech (Australia) Pty Limited | Amyloidosis; Systemic | 03/25 | 03/25 | | |
